Melanoma under 40
By Carole Renouf
17 November 2016
I spent a morning in clinic with one of MIA’s surgeons about a month ago. As each of her patients arrived, she inquired whether they would mind the CEO sitting in on their appointment because the CEO wanted to learn more about the experience of patients. Every single patient consented to having me present. They ranged from old to young, male to female, early to advanced melanoma and it was very moving for me to spend some time with them as they received everything from the worst news to the best. All the people with melanoma I met that day have stayed with me, but none more so than the young ones (under 40). It was the statistic that melanoma is the most common cancer in 15-39 year old Australians that really persuaded me to take this job.
A few years ago, when I was in a previous role, one of my proudest initiatives was the work we did reaching out to young women, those who got breast cancer in their 20s and 30s.
The impact of cancer on young lives is ferocious and wide-ranging. This is not to diminish in any way its significant impact on older lives, but when you are under 40 the experience of cancer tends to take more away across more aspects of your life and over a longer time. Also, as cancer services tend to be geared towards older people, you are likely to find less help and support suited to your needs and life stage.
The qualitative research that was done into breast cancer in young women revealed that the disease, diagnosis and treatment impacted issues as critical as future employment and career, finances, fertility, relationships and sexuality and self-image. If you would like to see footage from the press conference with affected young women, click here.
To my knowledge, no such research has yet been done in melanoma in Australia. Melanoma is the most common cause of cancer death in 20-39 year olds. In contrast to breast cancer, melanoma strikes both men and women (slightly more men) and therefore must assuredly involve additional issues to breast cancer. Yet, there is no body of evidence as to what these are, nor how to address them.
As we head towards 2017, I have set myself the goal of gathering the evidence from young Australians affected by melanoma of its impact on their lives and of any unmet needs they may have. This may mean a shift in the way we and others provide services.
For example, over 90% of melanoma – if caught early – is curable through surgery, so surgery remains a dominant treatment modality. A famous surgeon once said, “If you can’t cut it out, it’s not real” - yet studies show that psychosocial distress is very real in at least 30% of melanoma patients and I suspect even more real in the young. So is there an unmet need for more psychosocial support for under 40s affected by melanoma, for example?
If you’d like to share your experience and help me gather the evidence about the impact of melanoma on young Australians, please contact us at email@example.com for a personal interview. Your contribution would be greatly appreciated.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.